EXCLUSIVE: Alzamend Neuro Identifies Potential AL001 Dose Level For Upcoming Alzheimer's Study
Portfolio Pulse from Vandana Singh
Alzamend Neuro has identified a maximum tolerated dose (MTD) for developing AL001 from a multiple-ascending dose study. The company expects to initiate two AL001 Phase 2 trials for patients with mild to moderate Alzheimer's in Q1 of 2024 and submit FDA investigational new drug applications by the end of 2023.
June 22, 2023 | 11:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alzamend Neuro identified the maximum tolerated dose for AL001 and plans to initiate Phase 2 trials in Q1 2024 and submit FDA applications by the end of 2023.
The identification of the maximum tolerated dose for AL001 is a positive development for Alzamend Neuro, as it allows the company to move forward with Phase 2 trials and FDA applications. This progress in their drug development pipeline could potentially lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100